A Phase 2 interventional study of Zimura and Eylea in Idiopathic Polypoidal Choroidal Vasculopathy, sponsored by Ophthotech Corporation. Withdrawn at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-02-21.
Sponsored by Ophthotech Corporation (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing aflibercept in Polypoidal Choroidal Vasculopathy — 1 open to participants now, 1 under way, 1 of them phase 3. aflibercept · Polypoidal Choroidal Vasculopathy.
Among the 11 studies testing aflibercept in Polypoidal Choroidal Vasculopathy, this one is the 11th largest by enrollment, is the only one that started in 2018, is the only one in phase 2, and was the 7th registered.
54 studies on the registry are indexed under Polypoidal Choroidal Vasculopathy; 6 are open to participants now.
Browse Polypoidal Choroidal Vasculopathy studies →1 of the 11 studies testing aflibercept in Polypoidal Choroidal Vasculopathy is open now, in 1 country. Recruiting first, the newest first:
Yeungnam University College of Medicine · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 5 Polypoidal Choroidal Vasculopathy studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2018.
Median enrollment 48 across the 11 interventional studies. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 11 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ophthotech Corporation, one of the names counted as Astellas Pharma Inc. Under that name alone:
Ophthotech Corporation is the lead sponsor of 13 studies on the registry; none are open to participants now.
Astellas Pharma Inc has 2 studies filed under Polypoidal Choroidal Vasculopathy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing aflibercept in Polypoidal Choroidal Vasculopathy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To asses the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Eylea® in treatment experienced subjects with idiopathic polypoidal choroidal vasculopathy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zimura dosage 1 + Eylea 2 mg
Drug: Zimura · Drug: Eylea
Zimura dosage 2 + Eylea 2 mg
Drug: Zimura · Drug: Eylea
Adverse Events (AEs)
AEs
Time frame: 9 months
Start is estimated for Nov 2018; primary completion for Dec 2019, 13 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Avacincaptad pegol · Aflibercept
Polypoidal Choroidal Vasculopathy →